This content is machine translated Lung, kidney cancer and chronic myeloid leukemia What does modern clinical practice look like? At the DGHO Congress in Vienna, various aspects in clinical practice in non-small cell lung cancer (NSCLC), renal cell cancer (RCC) and chronic myeloid leukemia were addressed. In particular, the…
View Post 3 min This content is machine translated Non-Hodgkin's Lymphoma Pomalidomide in high-risk patients. Because data on the efficacy of pomalidomide in high-risk relapsed/refractory multiple myeloma populations are sparse, a phase II study set out to evaluate the agent in patients with GEP70 or…
View Post 2 min This content is machine translated Multiple Myeloma Media Workshop Which form of therapy is suitable for whom? At a media workshop during the ASH Congress in New Orleans, some key points of myeloma research were presented. They also discussed what these innovations mean for patients and used…
View Post 4 min This content is machine translated Metastatic colorectal carcinoma To what extent does aspirin affect survival? More recently, studies have shown that aspirin improves overall survival in subgroups with colorectal cancer, specifically those with PIK3CA mutations. To test whether regular aspirin use is associated with survival…
View Post 6 min This content is machine translated Non-Hodgkin's lymphoma and myelodysplastic syndrome What are the benefits of lenalidomide and pomalidomide? At the ASH Congress in New Orleans, the focus was on the efficacy and safety of lenalidomide plus low-dose dexamethasone in the treatment of patients with newly diagnosed multiple myeloma.…
View Post 4 min This content is machine translated Treatment of metastatic colorectal carcinoma. Patients with RAS wild type benefit in overall survival New data on first-line treatment of metastatic colorectal cancer were presented at the ASCO GI in San Francisco. The post-hoc analyses consistently confirm that RAS mutation status is an important…
View Post 4 min This content is machine translated HER2-positive breast cancer and lymphoma New applications and antibodies The antibody-drug conjugate trastuzumab emtansine, T-DM1 (Kadcyla®), is composed of the antibody trastuzumab and the chemotherapeutic agent DM1 and is currently being investigated for the treatment of HER2-positive cancers. It…
View Post 4 min This content is machine translated Hematology New possibilities thanks to targeted therapy At the DGHO congress in Vienna, the focus was on new targeted therapies designed to improve the quality of life of patients with malignant hematologic diseases. In particular, medical advances…
View Post 6 min This content is machine translated 5th Interdisciplinary Prostate Cancer Symposium Metastatic prostate cancer – New therapeutic options Prostate cancer is the most common male tumor in Western countries and is the second leading cause of cancer-related death in Switzerland. In particular, metastatic castration-resistant prostate cancer (mCRPC) is…
